The Czech Republic experience with erlotinib in the treatment of a non-selected non-small cell lung cancer (NSCLC) population of 2365 patients (pts)

Authors	SKŘIČKOVÁ Jana BORTLÍČEK Zbyněk HEJDUK Karel PEŠEK M. ZATLOUKAL P. KOLEK V. SALAJKA F. KOUBKOVÁ L. ČOUPKOVÁ H. ZEMANOVÁ M.
Year of publication	2012
Type	Conference abstract
MU Faculty or unit	Faculty of Medicine
Citation
Attached files	Skrickovlung_cancer_006.pdf
Description	This analysis, The Czech Republic experience with erlotinib in the treatment of a non-selected non-small cell lung cancer (NSCLC) population of 2365 patients, presented examines data obtained from the Czech population of NSCLC pts who received erlotinib.